New drug vs chemo for KRAS G12D pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new targeted drug, GFH375, against standard chemotherapy for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the new drug works better and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic cancer that has spread to other parts of your body (metastatic).
- You have already tried at least one standard cancer treatment (like chemotherapy) for your cancer.
- Your tumor has a specific genetic change called KRAS G12D (this is checked by your doctor).
- You have not been treated before with a drug that targets the KRAS G12D gene.
- Your cancer is measurable on scans (like CT or MRI), and you are expected to live at least 12 more weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GFH375 combined with either cetuximab or chemotherapy for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It's for those whose cancer has worsened after other treatments or who can't have standard therapy.
This study tests a new drug combined with chemotherapy for people with pancreatic cancer that has spread and has a KRAS gene mutation. It may help shrink tumors or slow their growth.
This trial tests three new targeted drug combinations for pancreatic cancer that has a specific genetic change (KRAS G12D). They are comparing the study drug alone versus combining it with other investigational drugs to see which works better.
This trial tests a new medicine (DN022150) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The combination may help shrink or slow the cancer better than chemotherapy alone.
This trial compares a new targeted pill (DN022150) with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12D gene change. It aims to see if the new drug works better at shrinking tumors and improving survival.
This trial tests a new experimental drug, RNK08954, for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and can help shrink or slow the cancer.
Hear when a new Metastatic Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.